Format

Send to

Choose Destination
Leuk Lymphoma. 2014 Dec;55(12):2830-4. doi: 10.3109/10428194.2014.904508. Epub 2014 Apr 22.

Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.

Author information

1
The National Center of Hematology , Baghdad , Iraq.

Abstract

Imatinib (Glivec(®)/Gleevec(®)) has shown long-term efficacy and safety in randomized trials. No large-scale studies have prospectively assessed the benefit-risk profile of an imatinib copy drug. We prospectively evaluated the response of patients with chronic myeloid leukemia in chronic phase in one institution. Patients with a complete hematologic response (n = 126) switched from branded imatinib to an imatinib copy drug. Subsequently, all patients switched back to the branded imatinib. Many patients in this study had a loss of hematologic response and tolerability issues with the imatinib copy drug. Hematologic response and tolerability improved upon retreatment with branded Glivec.

KEYWORDS:

Glivec/Gleevec; Imatib; Imatinib; chronic myeloid leukemia; complete hematologic response; copy drug

PMID:
24628295
DOI:
10.3109/10428194.2014.904508
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center